Sign up for our newsletter

Below is a report that DML News gives a 4 OUT OF 4 STARS trustworthiness rating. We base this rating on the following criteria:

  • Provides named sources
  • Reported by more than one notable outlet
  • Does not insert opinion or leading words
  • Includes supporting video, direct statements, or photos

Click here to read more about our rating system.

As the most reliable and balanced news aggregation service on the internet, DML News App offers the following information published by WSJ.com:

Gilead Sciences Inc. detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $3,120 for a typical patient.

The drugmaker on Monday disclosed its pricing plans as it prepares to begin charging for the drug in July. The U.S. has been distributing remdesivir donated by Gilead since the drug was authorized for emergency use in May.

The article goes on to state the following:

Under the company’s plans, Gilead will charge a higher price for most patients in the U.S., and a lower price for the rest of the developed world where governments directly negotiate drug prices. The lower price will be extended to some U.S. government agencies, such as the Department of Veterans Affairs, but not programs such as Medicare and Medicaid that don’t directly purchase medicines, a Gilead spokesman said.

Gilead said the government will be charged $390 a dose. The cost of the shortest, most common treatment course for each patient at that price will be $2,340, or $4,290 for a longer treatment course.

Nongovernment buyers will be charged $520 a dose, or $3,120 for a patient with the shorter course and $5,720 for the longer course.

To get more information about this article, please visit WSJ.com.

Sign up for our newsletter
Previous articleREPORT: Israel orders evangelical Christian media network God TV to take channel off air
Next articleREPORT: Judge Napolitano: Governments ‘Do Not Have The Authority’ To Mandate Mask-Wearing

2 COMMENTS

  1. Hydroxychloroquine is a lot cheaper, and it works, but thanks to FAKE NEWS, the FDA won’t let doctors use it, even though doctors in other countries have success with it! The pharmaceutical companies only care about making a buck, and not saving lives!

LEAVE A REPLY

Please enter your comment!
Please enter your name here